© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The discovery and mass production of Analgin monohydrate go back to the early 20th century when chemists scoured for pain relief options beyond the heavy side effects of opiates. Synthesized by Ludwig Knorr in Germany, Analgin marked a significant step forward for antipyretic and analgesic drugs. Its journey parallels advances in organic chemistry, especially the exploration of pyrazolone derivatives. For decades, Analgin made it into pharmacopeias across Europe, Latin America, and Asia, redefining relief protocols in crowded clinics and bustling emergency rooms. Even as regulatory scrutiny increased in some regions, other countries still saw enthusiastic adoption rooted in decades of trusted outcomes among both primary care doctors and patients looking for dependable pain relief.
Analgin monohydrate falls under the family of non-opioid analgesics. Its active ingredient stands as metamizole sodium, presented in a monohydrate crystalline form. Companies package it in tablet or injectable forms. Analgin supports febrile and pain management for headaches, toothaches, and acute injuries. Pharmacies in certain countries rely heavily on Analgin stock, serving a cross-section of people who struggle with pain but resist stronger interventions. Despite concerns about adverse effects in some populations, its lower cost and effectiveness have kept it relevant, especially where alternative medications remain inaccessible or unaffordable.
Analgin monohydrate appears as a white to slightly yellow, crystalline powder that dissolves quickly in water and alcohol, offering a neutral, almost tasteless experience upon oral administration. The chemical structure, C13H17N3O4SNa·H2O, shows methyl, amino, and sulfonate groups attached to a pyrazolone core. Melting point clocks in just above 165°C, while the compound's solubility ensures fast absorption through the digestive tract. The sodium ion boosts water solubility, making it suitable for injectable forms, necessary for rapid intervention in clinical settings.
Producers list the assay content of metamizole sodium monohydrate at not less than 99% purity, audited with advanced chromatographic techniques. Moisture content, heavy metals, and residual solvents get tracked within strict boundaries to pass international standards. Product labeling calls for clear hazard information, storage recommendations below 25°C, and usage instructions matching that country’s pharma regulations. Child-resistant packaging and tamper-evident seals protect users, and clear batch coding supports traceability in case of recalls. These practices hold up under the scrutiny of both health regulators and hospital procurement experts, driving consistent expectations in supply chains.
Manufacturers start with the synthesis of 4-methylaminoantipyrine from 1-phenyl-3-methyl-5-pyrazolone. The process continues as the intermediate undergoes sulfonation with chlorosulfonic acid, producing the sodium salt. The final step involves hydration, crystallizing the compound as the monohydrate. Operators run the process under controlled temperature and humidity to lock in the right crystal structure and chemical stability. Each lot passes through multiple purification cycles, washing out organic solvents and neutralizing acids, to offer a product that meets both clinical and industrial quality benchmarks.
Analgin demonstrates chemical reactivity typical for pyrazolone derivatives. Under acidic conditions, the sulfonate group can hydrolyze, while oxidation might occur with strong oxidants. Research circles have experimented with structural modifications, swapping side chains to tweak anti-inflammatory profiles or reduce rare adverse reactions. Some chemists look for analogues with similar pain-relieving activity but improved safety. Analgin’s chemistry allows for coupling with other actives, broadening therapeutic possibilities beyond standalone use.
Analgin monohydrate wears a long list of names around the world, underscoring its broad reach. Metamizole sodium, Dipyrone, Novalgin, and Algopyrin count among the most recognized. Drug formularies in Eastern Europe and South America often use these synonyms interchangeably. The wide spectrum of generic brands ensures competition and keeps prices low, supporting wide distribution through pharmacies and hospitals.
The manufacture and handling of Analgin monohydrate call for robust worker safety measures due to the risk of allergies and, rarely, agranulocytosis. Plants design workspaces with proper air extraction, mandatory gloves, laboratory coats, and goggles. International Good Manufacturing Practice (GMP) sets the floor for quality. Regular audits and cross-contamination checks minimize risk. Companies provide training on the safe handling of pyrazolone compounds. Pharmacovigilance programs encourage professionals and patients to report adverse events, so new risks can surface quickly. Where restrictions exist, pharmacy shelf access gets replaced with prescription-only dispensing, and sales data feeds into national pharmacosurveillance systems.
Doctors prescribe Analgin for short-term relief from intense pain, such as during dental procedures, sudden injuries, and some post-operative care. Emergency departments value its swift onset and the option to administer it intravenously for rapid action. Beyond human medicine, veterinarians use Analgin in livestock and companion animals who cannot take other NSAIDs comfortably. Developing countries see widespread use in rural clinics lacking resources for other pain relievers. Its affordability brings comfort to millions, especially in overstretched settings where cost shapes most medical decisions. Some health systems retain Analgin as a tool despite regulatory limits elsewhere, reflecting practical experience and population need.
Scientists keep investigating Analgin, seeking to better understand its mode of action, optimize dosing, and find safer structural cousins. Projects focus on mapping its metabolism pathways using advanced mass spectrometry and identifying which patients can safely benefit. New clinical studies challenge past assumptions about risk, particularly in genetically predisposed groups. Investigators also test Analgin combinations with other non-opioid analgesics, exploring additive or synergistic effects in managing complex pain scenarios. Industry interest stays strong, with efforts aimed at better formulations—injectables with fewer side effects, or oral tablets with improved bioavailability for users with sensitive digestive systems.
Analgin’s potential side effects put regulatory and scientific teams on high alert. Agranulocytosis—a sharp drop in white blood cells—haunts its safety profile and has led to bans in several high-income countries, yet remains a rare event in real-world usage. Epidemiological work continues to explore who faces the greatest risk, and how dosage or co-administration with other drugs might change outcomes. Biochemical studies look at the immune reaction that triggers these rare but serious events, hoping to predict or sidestep them through patient screening. Reports on liver and kidney toxicity remain less common, but careful population monitoring ensures alerts travel fast when clusters of adverse effects pop up.
The future of Analgin monohydrate pivots on balancing strong pain relief needs with an unwavering focus on safety. Regulatory agencies weigh incoming safety reports against deep-rooted public demand for fast, affordable pain control. While some countries clamp down, others champion further research and smarter screening. Digital health tools offer new ways to track adverse events and guide safer prescribing. Science may yet yield modifications of the Analgin molecule that shed its rare but serious risks. For millions in resource-limited settings, Analgin’s benefits argue for careful stewardship, measured use, and continuous innovation, keeping this workhorse medication alive for another generation facing the world’s daily aches and emergencies.
Pain disrupts daily life, whether it comes from simple headaches or muscle aches after a tough day. Analgin Monohydrate, known in some places as metamizole, aims to manage pain and bring down fever. It helps many who face toothaches, post-surgical aches, or severe migraines. In places where it's still widely available, doctors depend on it for patients dealing with acute pain when other medications don’t do enough.
People look for pain relief that acts fast without long waits. Analgin Monohydrate jumps into action for fever and pain when the usual options—paracetamol or ibuprofen—fall short. I grew up in Eastern Europe, where families kept a stash in the medicine cabinet. For my grandfather, who lived with chronic arthritis, Analgin Monohydrate offered him a few hours of comfort and the ability to move around.
Unlike medications that raise worries about addiction, such as opioids, Analgin Monohydrate has helped many with its non-narcotic profile. Hospitals often turn to it after surgeries to help patients rest without feeling overly groggy. It handles fevers that don’t budge with basic over-the-counter pills, making it valuable for kids and adults alike, especially before advanced therapies reach smaller clinics.
Not every good thing comes without a catch. Analgin Monohydrate drew attention not only for the relief it brought, but also the rare but serious side effects. Some people developed a dangerous drop in white blood cells, called agranulocytosis, which leaves the body open to deadly infections. Most people never face this risk, but for regulators in countries like the United States and much of Western Europe, the chance seemed high enough to ban or restrict it.
Parts of South America, Asia, and Eastern Europe still allow access, mainly under guidance from a doctor. Researchers dug into the reported risks and found that the highest danger linked to misuse or long-term, high-dose use, instead of one-off treatment. People with a history of allergic reactions or immune problems bear the most risk.
Doctors and nurses juggle the need to end pain with the job of keeping patients safe. Analgin Monohydrate offers affordable and rapid relief for millions, but any approach needs clear rules. Before prescribing, many clinics now run blood tests and follow up closely for warning signs. Some drug makers add tracking numbers and alerts to help trace rare reactions. Warnings on packaging in bold letters remind people not to ignore side effects like sore throat or fever.
Global health bodies such as the World Health Organization continue to collect data, weighing the benefits against the risks for different communities. Local training for healthcare workers helps spot problems early, and public health campaigns push for safe use, not blind trust in a pill.
Access to effective pain relief should not depend on location or income. Analgin Monohydrate proves useful where hospitals run out of fancier drugs. Each country faces the same balancing act—providing strong pain relief without endangering lives. Analgin has earned trust in many regions through direct experience, but bringing that trust up to modern safety standards benefits everyone.
Analgin monohydrate, known by the name Metamizole in some regions, has a reputation for strong pain relief. Used for decades across several countries, it tackles moderate to severe pain and fever, especially in cases where other drugs don't cut it. People might find themselves searching for reliable dosing information—what’s safe, what’s effective, and what experts actually recommend.
Misjudging the amount of a drug like Analgin doesn’t just mean a headache that lingers. It raises real risks. Analgin’s effectiveness as a painkiller can’t erase the fact that excessive use runs the risk of serious side effects, such as agranulocytosis—a sharp drop in white blood cells that weakens the immune system. Medical authorities in the World Health Organization and European Medicines Agency highlight this rare but dangerous reaction as the top reason for caution.
Most clinicians settle on a starting dose for adults between 500mg and 1000mg per dose, with the maximum daily limit set at 4000mg. Typical pain or fever may call for a single 500mg tablet, repeating every 6 to 8 hours. The gap between doses lets the body process the drug safely. Patients shouldn’t go over 4 grams in 24 hours, no matter how severe the pain. Beyond this, trouble may follow, including blood disorders or kidney issues.
Kids and elderly patients face different challenges. Doctors usually recommend 8–16 mg per kilogram of body weight, split over three or four doses during the day. Giving the right amount can be a headache for parents, which is why clear guidance from a pediatrician is so important. Elderly people or those with chronic health problems often need less, as their bodies process drugs more slowly. Giving the same strength to an 80-year-old as a healthy 30-year-old can cause more harm than good.
As someone who has seen many pain patients over the years, I don’t like taking chances with strong medication, especially without lab checks. Too many people think, “If it’s over-the-counter in one country, it must be safe.” That just isn’t true for Analgin. Monitoring for fever, skin reactions, or signs of infection is not just a nice-to-have—it’s a non-negotiable part of using this drug. Healthcare professionals need to walk patients through the signs of problems and take regular blood tests for anyone on Analgin for more than a few days.
Not everyone reads the fine print on a leaflet, so clear instructions at the pharmacy or clinic matter. Digital reminders or educational apps could help keep patients on track. Regulations could require a prescription for Analgin to encourage doctor supervision. Research teams could focus on finding safer painkillers, but for now, smart monitoring and strict dosing guidelines are what keep patients safe. It takes a team effort: doctors, pharmacists, and patients working together reduce the risk of harm and boost the benefit of every pill.
Analgin, also recognized as metamizole, has served as a popular painkiller and fever reducer in many parts of the world. Growing up, stories often included someone reaching into the medicine cabinet for a trusted pill to push away a headache or muscle pain. Analgin seemed like a quick fix, but health professionals have pointed out concerns that stick with you long after the pain fades.
My own family faced the reality of pharmaceutical allergies not long ago—a simple course of antibiotics led to hives and a late-night hospital trip. Analgin has its own risk of serious allergic reactions, including rash, swelling of the face or throat, and trouble breathing. These reactions can move fast and require immediate emergency care.
One of the most severe problems linked to Analgin is agranulocytosis. This rare but dangerous drop in white blood cells can crash the immune system. Without enough white cells, the body loses its defense against common infections. It’s not just a theoretical issue either; cases from countries like India, Brazil, and Russia show how people collapsed with infections their bodies could not fight off.
Doctors have tracked other blood-related effects tied to Analgin use, like anemia or a drop in platelets leading to unexplained bruising or bleeding gums. I’ve met patients in clinics who thought they were fighting off a simple cold but ended up facing fatigue from low hemoglobin—lab results showing that cell counts rarely bounce back with more of the same medicine.
Beyond the blood, there’s risk to organs too. Analgin may strain the kidneys or liver, especially with frequent use. Abdominal pain, dark pee, or yellowing skin often send people searching for answers. Those with older family members or chronic illnesses understand how every medicine can turn dangerous quickly if the kidneys can’t filter it out.
Side effects sneak into daily life in less dramatic ways as well. Users report nausea, dizziness, headaches, and sweating soon after taking Analgin. For someone older, a dizzy spell in the kitchen can lead to a bad fall. Nausea wrecks your appetite and, if ignored, makes simple routines a burden.
Fact-guided health authorities in parts of Europe and North America pulled Analgin from pharmacy shelves decades ago. The risk for serious blood disorders outweighed the benefit for most people. The World Health Organization notes that safer alternative painkillers—like paracetamol or ibuprofen—usually do the trick, provided you stick to instructions. Acetaminophen, for example, rarely causes immune issues, and you can spot side effects early.
Patients should always check with their doctors before picking up strong pain medicines—especially if the medicine has a mixed record overseas. Pharmacists can provide safer options, particularly for kids, seniors, or anyone with chronic health troubles. Every household benefits from keeping phone numbers for local poison centers handy and knowing what to do if strange symptoms appear after taking any drug.
Public health campaigns and clear information from doctors and pharmacists save lives. Sharing experiences and medical facts can lead friends and family toward better choices. Reviewing the label, looking up side effects from trusted sources like hospital websites, and being open with healthcare providers all help avoid dangerous surprises with pain medication.
Every pill carries a story—sometimes relief, sometimes risk. Analgin reminds us to weigh those risks and look for answers, not just comfort, in the medicine cabinet.
Analgin monohydrate, also called metamizole, carries a reputation for its strong pain-relieving abilities. While it continues to offer relief in many parts of the world, discussions around its use always seem to come with a warning label. Back in my pharmacy days, I noticed people often reached for Analgin hoping for a quick cure, not always paying attention to which other pills they’d taken that morning.
Taking several drugs at once feels common these days, especially for people managing chronic illnesses. Mixing Analgin with other medicines can stir up trouble in more ways than most expect. Analgin changes how the body processes things—especially in the liver. Tossing it in with certain antidepressants, blood thinners, or even common antibiotics means you might tip a balance you never realized you were walking.
A few years back, I met a neighbor who ended up in the emergency room not because Analgin itself triggered a problem, but because it mixed poorly with their heart medication. Liver enzymes struggled with both drugs, and side effects multiplied. Medications like warfarin or lithium—just to name two—already play a delicate game in the bloodstream, and Analgin may throw off their rhythm.
One piece that keeps surfacing in research is the risk of a rare blood issue called agranulocytosis. Countries such as the US and UK set aside Analgin for this reason, pushing alternatives instead. Combining it with medicines that already lower white blood cell counts (think some anti-cancer or rheumatoid arthritis drugs) can steer people toward real danger.
I have seen friends from my hometown in Central Europe, where Analgin is more accepted, get caught off guard by this. They didn’t read labels or ask the pharmacist. Blood tests revealed a dip in immune strength, which wouldn’t have surfaced had their doctor known about all the medicines in play. It’s a reminder that no matter how long a medicine has been in the cabinet, it demands respect in new combinations.
Talking through your full medication list with a healthcare provider tops any advice I’d share. Doctors and pharmacists keep up with the latest studies, which can flag new or hidden drug clashes. My own routine questions at the pharmacy counter—“Are you using anything new?”—saved more than one customer from a headache or worse.
Regular blood tests don’t just build trust; they also catch problems early. Checking liver and kidney function, as well as blood counts, guides the decision whether to carry on with Analgin. If your list of medications keeps growing, sometimes changing to a different painkiller or spacing out doses can make all the difference.
For anyone living with multiple prescriptions, a written record—maybe even just a simple notebook—goes a long way. Bring it to every appointment. Share it with every new doctor. It cuts down on surprises. No one wants pain relief at the cost of a bigger problem. Respecting interactions, keeping the conversation open, and listening to those warning signs matters more than any quick fix.
Analgin monohydrate, also known as metamizole, comes up a lot in conversations about pain relief and fever reduction. Parents often look for quick solutions for a child’s fever, and expecting mothers deal with everything from headaches to tooth pain. Every parent wants to protect their child, and no mother wants unnecessary risk during pregnancy. The question about safety with this medicine never seems to fade away, especially as stories keep circulating and some countries still sell it at local pharmacies.
Years ago, Analgin gained popularity for its ability to knock down high fevers and pain that didn’t seem to let up. European medical regulators pulled the brakes when they realized the risks were more serious than anyone wanted to believe. Several well-documented studies found that metamizole sometimes triggers agranulocytosis, a life-threatening drop in white blood cells that leaves people wide open to infections. This side effect doesn’t happen to everyone, but there is no warning sign before it strikes. Studies published in the British Medical Journal and from the World Health Organization regularly mention agranulocytosis related to Analgin use.
Kids, especially those under twelve, don’t have the same ability as adults to handle certain medications. Their immune systems lag behind in strength, and they don’t clear drugs from their bodies as quickly. Analgin can lower fevers, but other safer choices are on the shelf, like acetaminophen and ibuprofen. The risks tied to agranulocytosis just feel too heavy when better-studied options work effectively. I’ve spoken with pediatricians who won’t prescribe Analgin for that very reason. Many countries, including the United States, the UK, and parts of Scandinavia, banned its use. This kind of united health policy sends a strong message: it’s not worth the risk for children.
Pregnancy brings enough challenges without adding medication worries. Analgin passes through the placenta, and research in animals points to possible fetal harm. Enough human data hasn’t surfaced to erase concerns. European Medicines Agency and the FDA both warn pregnant women to avoid this drug. During pregnancy, pain and fever should get managed with safer alternatives. Most medical professionals lean toward acetaminophen for short-term use, unless personal medical circumstances suggest otherwise. Many obstetricians have seen birth defects and complications linked to less-tested drugs, and few are willing to gamble on the unknowns tied to Analgin.
No one enjoys seeing their child or loved one suffer from pain or fever. The goal should be symptom relief without trading one problem for another. Doctors trust treatments that have stood the test of time and study. Consulting a healthcare provider or a pediatrician makes sense before picking up any drug, especially for something as serious as pain or persistent fever. Good advice never goes out of style: choose medications that have reinforced their safety through decades of research and clear health regulations. For families in countries where Analgin remains on shelves, awareness and caution make all the difference. Sometimes, old habits and familiar remedies don’t always serve us best—newer may sometimes mean safer, especially for the most vulnerable among us.
| Names | |
| Preferred IUPAC name | sodium 4-[ethyl(dimethyl)amino]benzenesulfonate monohydrate |
| Other names |
Metamizole Monohydrate Dipyrone Monohydrate Sodium Metamizole Monohydrate |
| Pronunciation | /ˈæn.æl.dʒɪn ˌmɒn.oʊˈhaɪ.dreɪt/ |
| Identifiers | |
| CAS Number | 600-33-3 |
| Beilstein Reference | 607700 |
| ChEBI | CHEBI:6105 |
| ChEMBL | CHEMBL21022 |
| ChemSpider | 27338569 |
| DrugBank | DB04817 |
| ECHA InfoCard | 03fc52e6-4b88-4cd8-8e87-75e2c8ac3eda |
| EC Number | 206-104-4 |
| Gmelin Reference | 30254 |
| KEGG | D07585 |
| MeSH | Dipyrone |
| PubChem CID | 23668479 |
| RTECS number | SL8750000 |
| UNII | 7R1N6K39DQ |
| UN number | 2811 |
| CompTox Dashboard (EPA) | DTXSID8038643 |
| Properties | |
| Chemical formula | C13H17N3O4S |
| Molar mass | 372.43 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.6 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -0.02 |
| Acidity (pKa) | 15.1 |
| Basicity (pKb) | 5.75 |
| Magnetic susceptibility (χ) | -7.2e-6 |
| Refractive index (nD) | 1.544 |
| Dipole moment | 3.87 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 247.0 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -302.62 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -1777 kJ mol⁻¹ |
| Pharmacology | |
| ATC code | N02BB02 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause damage to organs through prolonged or repeated exposure. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS05,GHS07 |
| Signal word | Danger |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | P264, P270, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | NFPA 704: 2-1-0 |
| Autoignition temperature | 464°C |
| Lethal dose or concentration | LD50 (oral, rat): 3,870 mg/kg |
| LD50 (median dose) | LD50 (median dose): 3,150 mg/kg (rat, oral) |
| NIOSH | SA9275000 |
| PEL (Permissible) | 10 mg/m3 |
| REL (Recommended) | Analgin Monohydrate 500 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
4-Aminophenazone Dipyrone Metamizole Sodium Antipyrine |
